Following the recent ASX Announcement on 1 Oct 2019, Actinogen Medical held a conference call to give an update on the results from the XanaHES trial. “These are the results we have been looking for. They are hugely important for the development of Xanamem and for the potential for Xanamem to treat Alzheimer’s disease and other conditions associated with cognitive impairment” said Dr Bill Ketelbey
The Annual General Meeting of Shareholders will be held at the offices of K & L Gates, Level 31, 1 O’Connell Street, Sydney, 2000 on Monday, 25 November 2019, commencing at 11.00am AEDT
Actinogen is delighted to announce results from the XanaHES (Xanamem in Healthy Elderly Subjects) trial. The Company hosted a conference call at 10:30am (AEST) on Tuesday 1st October 2019. The presentation referred to in the call, is attached to this announcement.
Actinogen Medical is an ASX-listed biotechnology company developing innovative treatments for Alzheimer’s disease and the cognitive impairment associated with neurodegenerative diseases and metabolic diseases, like Type 2 diabetes.
Our management team and scientific advisory board includes world-renowned Alzheimer’s disease and dementia researchers, and industry specialists in drug design and clinical trial management.
Actinogen Medical’s drug candidate Xanamem has been specifically designed to block the production of cortisol in the brain. Drugs that reduce cortisol in the brain offer a promising new approach to slowing, or even preventing, the cognitive decline associated with Alzheimer’s disease.
Actinogen Medical has completed enrolment into XanADu, an international multi-site Phase II efficacy and safety trial of Xanamem in patients with mild Alzheimer’s disease. Recruitment and treatment of patients started in 2017, with results expected in Q2 CY19.
"Given the growing number of people with Alzheimer's and the critical importance of finding effective new drugs to treat this disease, our hope is that the development of Xanamem will make a real difference to Alzheimer's patients, and their carers and families worldwide."
|24.10.2019||R&D Tax Incentive rebate received of $4.58 million|
|24.10.2019||September 2019 Quarterly Update|
|22.10.2019||Annual Report to shareholders year ended 30 June 2019|
|22.10.2019||ACW – Notice of Annual General Meeting/Proxy Form|
|01.10.2019||Cognitive improvement demonstrated with Xanamem|